论文部分内容阅读
目的:观察变应原疫苗(商品名阿罗格,简称NHD)对变态反应性鼻炎患者血清中Th1、Th2细胞水平的影响。方法:3年期间收集30位变应性鼻炎患者,15例(A组)根据变应原进行特异性免疫治疗,15例(B组)仅鼻用糖皮质激素,观察治疗前后的临床疗效及免疫学标志白细胞介素-2(IL-2)、白细胞介素-13(IL-13)的变化情况。结果:A组(特异性免疫治疗组)有效率91.83%,B组(鼻用糖皮质激素组)有效率89.67%。A组变应性鼻炎患者在经NHD治疗后血清Th1细胞因子IL-2含量显著增高,而Th2细胞因子IL-13含量显著减少,治疗前后比较差异有统计学意义(P<0.05)。B组IL-2、IL-13含量治疗前后差异无统计学意义(P>0.05)。结论:特异性免疫治疗是治疗变应性鼻炎的有效方法。用NHD特异性免疫治疗能通过对变应性鼻炎患者血中Th1/Th2细胞产生的细胞因子IL-2、IL-13比例的平衡,来纠正Th1/Th2细胞失平衡,能明显改善患者的临床症状,Th1/Th2平衡假说得到初步证实。
Objective: To observe the effects of allergen vaccine (Aloe, NHD) on the levels of Th1 and Th2 cells in patients with allergic rhinitis. Methods: Thirty patients with allergic rhinitis were collected during the three years. Fifteen patients (group A) received specific immunotherapy based on allergen and 15 patients (group B) received nasal glucocorticoid only. Immunological markers of interleukin -2 (IL-2), interleukin-13 (IL-13) changes. Results: The effective rate of group A (specific immunotherapy group) was 91.83%, that of group B (nasal glucocorticoid group) was 89.67%. A group of allergic rhinitis patients after treatment of NHD serum Th1 cytokine IL-2 content was significantly increased, while Th2 cytokine IL-13 content was significantly reduced, before and after treatment was statistically significant difference (P <0.05). The levels of IL-2 and IL-13 in group B had no significant difference before and after treatment (P> 0.05). Conclusion: Specific immunotherapy is an effective treatment for allergic rhinitis. NHD-specific immunotherapy can correct the imbalance of Th1 / Th2 cells by balancing the proportion of cytokines IL-2 and IL-13 produced by Th1 / Th2 cells in patients with allergic rhinitis, and can significantly improve the clinical performance of patients Symptoms, Th1 / Th2 balance hypothesis was initially confirmed.